Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Reported Saturday, BridgeBio Pharma Reports 69% Reduction In All-Cause Mortality And First Cardiovascular Hospitalization Through Month 30 In V142I Variant ATTR-CM

Author: Benzinga Newsdesk | November 10, 2025 04:24am

- Simultaneously published in JAMA Cardiology along with moderated posters at AHA, acoramidis demonstrated:

59% risk reduction in ACM in the ATTR-CM variant population at Month 42 (p=0.032) compared to patients initially randomized to placebo in the ATTRibute-CM study
69% risk reduction in ACM/ first CVH through Month 30 compared to placebo (p=0.016) and a 69% risk reduction in ACM through Month 42 (p=0.045) in ATTR-CM participants with the genetic variant p.Val142Ile (V142I, V122I) compared to patients initially randomized to placebo in the ATTRibute-CM study

- This is the first report of clinical benefit of this magnitude observed in this high-risk population with significant unmet need

Posted In: BBIO